Orthovisc Injectable Intra-Articular Devices
Anika Therapeutics, Inc. · Decision date Aug 28, 2026
What did the FDA decide?
FDA records P030019/S028 as a supplement to PMA P030019, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 28, 2026.
FDA approval order statement
the replacement of reusable components with single-use, presterilized components for use during transfer steps of the formulation and fill process during manufacturing of the subject sodium hyaluronate devices
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Orthopedic
- Decision date
- Aug 28, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P030019/S028
- Regulatory pathway
- PMA supplement
- Applicant
- Anika Therapeutics, Inc.
- Product code
- MOZ
- Decision code
- OK30
- Decision date
- Aug 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Acid, hyaluronic, intraarticular.
- Applicant
- Anika Therapeutics, Inc.
- Product code
- MOZ
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P030019/S028 received
Application receipt date recorded by FDA.
P030019/S028 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P030019. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code MOZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Gel-OneP080020/S056 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
SUPARTZ FXP980044/S067 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
EUFLEXXA (1% sodium hyaluronate)P010029/S043 | Ferring Pharmaceuticals, Inc. | PMA supplement | Sep 2, 2026 | FDA |
GEL-ONEP080020/S057 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
SUPARTZ FXP980044/S068 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Anika Therapeutics, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 32 Wiggins Ave., Beford, MA, 01730
Sources and methodology
- Original FDA record: P030019/S028
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


